CSIMarket Company Name, Ticker, Customers, else..
 
Polypid Ltd  (NASDAQ: PYPD)
 

Polypid Ltd's Suppliers Performance

PYPD's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
PYPD Costs vs Sales of Suppliers Growth

• More on PYPD Suppliers






Polypid Ltd's Comment on Supply Chain


The company depends on third-party suppliers for certain raw materials, including the active pharmaceutical ingredient, required to manufacture its product candidates. Some raw materials are sourced from a limited number of suppliers, with reliance on sole providers in certain cases. The company does not control raw material availability and faces risks such as reduced manufacturing control, potential termination of supplier agreements, and disruptions unrelated to its operations. Certain suppliers must achieve cGMP compliance and establish a drug master file before the company can submit its NDA for D-PLEX 100. Supplier failure to meet contractual or regulatory requirements could delay NDA submission and clinical trials. The company has not yet finalized binding agreements with some third-party manufacturers for raw materials and products needed for commercialization and may encounter challenges negotiating such agreements on commercially reasonable terms.

Polypid Ltd's Comment on Supply Chain


The company depends on third-party suppliers for certain raw materials, including the active pharmaceutical ingredient, required to manufacture its product candidates. Some raw materials are sourced from a limited number of suppliers, with reliance on sole providers in certain cases. The company does not control raw material availability and faces risks such as reduced manufacturing control, potential termination of supplier agreements, and disruptions unrelated to its operations. Certain suppliers must achieve cGMP compliance and establish a drug master file before the company can submit its NDA for D-PLEX 100. Supplier failure to meet contractual or regulatory requirements could delay NDA submission and clinical trials. The company has not yet finalized binding agreements with some third-party manufacturers for raw materials and products needed for commercialization and may encounter challenges negotiating such agreements on commercially reasonable terms.







PYPD's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Polypid Ltd 84.38 0.00 29.02 59
SUBTOTAL 0.00 0.00 0.00 -


Sources: Polypid Ltd's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Polypid Ltd’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.